$141.51
3.14% day before yesterday
Nasdaq, May 02, 10:00 pm CET
ISIN
US7599161095
Symbol
RGEN

Repligen Corporation Stock price

$141.51
+10.59 8.09% 1M
+1.98 1.42% 6M
-2.43 1.69% YTD
-24.80 14.91% 1Y
-17.31 10.90% 3Y
+27.57 24.20% 5Y
+110.39 354.72% 10Y
Nasdaq, Closing price Fri, May 02 2025
+4.31 3.14%
ISIN
US7599161095
Symbol
RGEN
Sector
Industry

Key metrics

Market capitalization $7.95b
Enterprise Value $7.94b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 66.28
EV/Sales (TTM) EV/Sales 12.20
P/S ratio (TTM) P/S ratio 12.22
P/B ratio (TTM) P/B ratio 4.00
Revenue growth (TTM) Revenue growth 4.88%
Revenue (TTM) Revenue $650.43m
EBIT (operating result TTM) EBIT $26.98m
Free Cash Flow (TTM) Free Cash Flow $119.74m
Cash position $697.23m
EPS (TTM) EPS $-0.41
P/E forward 160.64
P/S forward 11.22
EV/Sales forward 11.20
Short interest 7.78%
Show more

Is Repligen Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,786 stocks worldwide.

Repligen Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

20 Analysts have issued a Repligen Corporation forecast:

15x Buy
75%
5x Hold
25%

Analyst Opinions

20 Analysts have issued a Repligen Corporation forecast:

Buy
75%
Hold
25%

Financial data from Repligen Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
650 650
5% 5%
100%
- Direct Costs 349 349
0% 0%
54%
302 302
12% 12%
46%
- Selling and Administrative Expenses 134 134
37% 37%
21%
- Research and Development Expense 44 44
5% 5%
7%
125 125
5% 5%
19%
- Depreciation and Amortization 98 98
10% 10%
15%
EBIT (Operating Income) EBIT 27 27
36% 36%
4%
Net Profit -23 -23
198% 198%
-4%

In millions USD.

Don't miss a Thing! We will send you all news about Repligen Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Repligen Corporation Stock News

Neutral
Seeking Alpha
5 days ago
Repligen Corporation (NASDAQ:RGEN ) Q1 2025 Earnings Conference Call April 29, 2025 8:30 AM ET Company Participants Jacob Johnson - VP, IR Olivier Loeillot - President, CEO & Director Jason Garland - CFO & Chief Compliance Officer Conference Call Participants Rachel Vatnsdal - JPMorgan Dan Arias - Stifel Puneet Souda - Leerink Partners Justin Bowers - Deutsche Bank Subbu Nambi - Guggenheim Secu...
Neutral
GlobeNewsWire
5 days ago
WALTHAM, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its first quarter of 2025, covering the three-month period ended March 31, 2025. The company is also providing updated financial guidance for the full year 2025.
Neutral
GlobeNewsWire
26 days ago
WALTHAM, Mass., April 08, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment of Jacob Johnson as Vice President, Investor Relations. In this role, Mr. Johnson will lead the investor relations team's engagement with the investment community, reporting to the company's Chief Financial Officer, Jason K. Garland. Most recently, Mr. Johnson served as Managing...
More Repligen Corporation News

Company Profile

Repligen Corp. provides advanced bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. The firm serves through the following product lines: Chromatography; Filtration; and OEM Products (Proteins). The Chromatography product line includes a number of products used in the downstream purification and quality control of biological drugs. The Filtration products offer a number of advantages to manufacturers of biologic drugs at volumes that span from pilot studies to clinical and commercial-scale production. The OEM products are represented by Protein A affinity ligands, which are a critical component of Protein A chromatography resins used in downstream purification, and cell culture growth factor products. The company was founded by Alexander G. Rich and Paul R. Schimmel in May 1981 and is headquartered in Waltham, MA.

Head office United States
CEO Olivier Loeillot
Employees 1,778
Founded 1981
Website www.repligen.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today